By Marwa Mahmoud
An executive at the French pharmaceutical company, Sanofi, said that the price of the Corona vaccine that the company is currently developing with GlaxoSmithKline will be about 10 euros, or the equivalent of only 11 dollars.
In an interview with Radio France Internationale, Market Watch published a summary of it, Oliver Bouguilott, head of the company’s operations in France, said that the price of the vaccine may even be lower than the price specified in advance, noting that the company takes into account the availability of the vaccine at an appropriate price with the high expected demand for it. If successful.
Bogliot added that company hopes the vaccine will pass all safety standards during the next few months, provided that it will be put on the market in the first half of this year at the latest, at a time when the company started human trials of the vaccine in cooperation with the British company only last month.
The head of the company’s operations in France talked about the company’s direction to launch its unit for manufacturing active pharmaceutical ingredients in the capital market during the next few months, as the French parent company listed on the Paris Stock Exchange seeks to provide more liquidity for its business and future research in the pharmaceutical industry.
“The idea here is that we are thinking of creating a European giant for the components of the pharmaceutical industry and using liquidity to fund future expansions,” Bogliot said.
Last July, Reuters quoted unnamed sources as saying that the fledgling company, which is expected to be listed in the money market, would be valued between one billion and two billion euros.
Last February, the French company said it plans to launch its pharmaceutical manufacturing activities on Paris Stock Exchange by 2022 before it works to accelerate the offering plans in conjunction with manufacturing the Corona vaccine in cooperation with the British company GlaxoSmithKline.
The shares of the French company rose in the first session of the week by about 2.5% after the announcement of its pricing plans for the expected Corona virus vaccine.
